{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T09:52:48Z","timestamp":1760953968768,"version":"3.37.3"},"reference-count":94,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2013,6,21]],"date-time":"2013-06-21T00:00:00Z","timestamp":1371772800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0066536","type":"journal-article","created":{"date-parts":[[2013,6,21]],"date-time":"2013-06-21T21:27:49Z","timestamp":1371850069000},"page":"e66536","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":18,"title":["Mutant Native Outer Membrane Vesicles Combined with a Serogroup A Polysaccharide Conjugate Vaccine for Prevention of Meningococcal Epidemics in Africa"],"prefix":"10.1371","volume":"8","author":[{"given":"Rolando","family":"Pajon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew M.","family":"Fergus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan M.","family":"Granoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2013,6,21]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0035-9203(99)90106-2","article-title":"Manson Lecture. Meningococcal meningitis in Africa","volume":"93","author":"B Greenwood","year":"1999","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1086\/648963","article-title":"Epidemiological profile of meningococcal disease in the United States","volume":"50","author":"LH Harrison","year":"2010","journal-title":"Clin Infect Dis"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1086\/649209","article-title":"Changes in <italic>Neisseria meningitidis<\/italic> disease epidemiology in the United States, 1998\u20132007: implications for prevention of meningococcal disease","volume":"50","author":"AC Cohn","year":"2010","journal-title":"Clin Infect Dis"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"B51","DOI":"10.1016\/j.vaccine.2009.04.063","article-title":"Global epidemiology of meningococcal disease","volume":"27","author":"LH Harrison","year":"2009","journal-title":"Vaccine"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1016\/S0140-6736(03)13494-0","article-title":"Meningococcal conjugate vaccine for Africa: a model for development of new vaccines for the poorest countries","volume":"361","author":"L Jodar","year":"2003","journal-title":"Lancet"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.vaccine.2008.11.065","article-title":"Preparation and characterization of an immunogenic meningococcal group A conjugate vaccine for use in Africa","volume":"27","author":"CH Lee","year":"2009","journal-title":"Vaccine"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1377\/hlthaff.2011.0295","article-title":"Product development partnerships hit their stride: lessons from developing a meningitis vaccine for Africa","volume":"30","author":"DM Bishai","year":"2011","journal-title":"Health affairs"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"B13","DOI":"10.1016\/j.vaccine.2009.04.062","article-title":"Epidemic meningitis due to Group A <italic>Neisseria meningitidis<\/italic> in the African meningitis belt: a persistent problem with an imminent solution","volume":"27","author":"F Marc LaForce","year":"2009","journal-title":"Vaccine"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1056\/NEJMoa1003812","article-title":"Immunogenicity and safety of a meningococcal A conjugate vaccine in Africans","volume":"364","author":"SO Sow","year":"2011","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"B40","DOI":"10.1016\/j.vaccine.2011.12.073","article-title":"Effectively introducing a new meningococcal A conjugate vaccine in Africa: the Burkina Faso experience","volume":"30","author":"MH Djingarey","year":"2012","journal-title":"Vaccine"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S1473-3099(12)70168-8","article-title":"Serogroup A meningococcal conjugate vaccination in Burkina Faso: analysis of national surveillance data","volume":"12","author":"RT Novak","year":"2012","journal-title":"Lancet Infect Dis"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Kristiansen PA, Diomande F, Ba AK, Sanou I, Ouedraogo AS, et al.. (2012) Impact of the Serogroup A Meningococcal Conjugate Vaccine, MenAfriVac, on Carriage and Herd Immunity. Clin Infect Dis <comment>DOI <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/dx.doi.org\/10.1093\/cid\/cis892\" xlink:type=\"simple\">10.1093\/cid\/cis892<\/ext-link><\/comment>","DOI":"10.1093\/cid\/cis892"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1586\/14760584.5.3.319","article-title":"Meningococcal serogroup W135 in the African meningitis belt: epidemiology, immunity and vaccines","volume":"5","author":"JE Mueller","year":"2006","journal-title":"Expert Rev Vaccines"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1086\/511646","article-title":"Meningococcal meningitis: unprecedented incidence of serogroup X-related cases in 2006 in Niger","volume":"44","author":"P Boisier","year":"2007","journal-title":"Clin Infect Dis"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"B26","DOI":"10.1016\/j.vaccine.2011.12.032","article-title":"The changing and dynamic epidemiology of meningococcal disease","volume":"30","author":"SA Halperin","year":"2012","journal-title":"Vaccine"},{"key":"ref16","first-page":"692","article-title":"MenACWY-CRM, a novel quadrivalent glycoconjugate vaccine against <italic>Neisseria meningitidis<\/italic> for the prevention of meningococcal infection","volume":"11","author":"D Pace","year":"2009","journal-title":"Curr Opin Mol Ther"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"170","DOI":"10.4161\/hv.7.2.13717","article-title":"Meningococcal glycoconjugate vaccines","volume":"7","author":"R Gasparini","year":"2011","journal-title":"Hum Vaccin"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/nrd3194","article-title":"Meningococcal group A, C, Y and W-135 conjugate vaccine","volume":"9","author":"LH Harrison","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1001\/jama.2007.57-c","article-title":"A multivalent conjugate vaccine for prevention of meningococcal disease in infants","volume":"299","author":"LH Harrison","year":"2008","journal-title":"JAMA"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0140-6736(83)90340-9","article-title":"Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis","volume":"2","author":"J Finne","year":"1983","journal-title":"Lancet"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1084\/jem.20021911","article-title":"Vaccination against <italic>Neisseria meningitidis<\/italic> using three variants of the lipoprotein GNA1870","volume":"197","author":"V Masignani","year":"2003","journal-title":"J Exp Med"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1128\/IAI.72.4.2088-2100.2004","article-title":"Vaccine potential of the <italic>Neisseria meningitidis<\/italic> 2086 lipoprotein","volume":"72","author":"LD Fletcher","year":"2004","journal-title":"Infect Immun"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"501","DOI":"10.4049\/jimmunol.177.1.501","article-title":"The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance","volume":"177","author":"G Madico","year":"2006","journal-title":"J Immunol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"I40","DOI":"10.1016\/j.vaccine.2008.11.060","article-title":"Factor H and Neisserial pathogenesis","volume":"26","author":"JA Welsch","year":"2008","journal-title":"Vaccine"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1016\/j.vaccine.2010.11.072","article-title":"Distribution of factor H binding protein beyond serogroup B: variation among five serogroups of invasive <italic>Neisseria meningitidis<\/italic> in South Africa","volume":"29","author":"KM Mothibeli","year":"2011","journal-title":"Vaccine"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1086\/600141","article-title":"Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B <italic>Neisseria meningitidis<\/italic>","volume":"200","author":"E Murphy","year":"2009","journal-title":"J Infect Dis"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1086\/656741","article-title":"Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy","volume":"51","author":"J Findlow","year":"2010","journal-title":"Clin Infect Dis"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.1097\/INF.0b013e3181f59f6d","article-title":"Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial","volume":"29","author":"MD Snape","year":"2010","journal-title":"Pediatr Infect Dis J"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"6163","DOI":"10.1016\/j.vaccine.2012.07.065","article-title":"A bivalent <italic>Neisseria meningitidis<\/italic> recombinant lipidated factor H binding protein vaccine in young adults: Results of a randomised, controlled, dose-escalation phase 1 trial","volume":"30","author":"PC Richmond","year":"2012","journal-title":"Vaccine"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1097\/INF.0b013e31826327e4","article-title":"Safety and Immunogenicity of a Meningococcal B Bivalent rLP2086 Vaccine in Healthy Toddlers Aged 18\u201336 Months: A Phase 1 Randomized-controlled Clinical Trial","volume":"31","author":"HS Marshall","year":"2012","journal-title":"Pediatr Infect Dis J"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S1473-3099(12)70087-7","article-title":"Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial","volume":"12","author":"PC Richmond","year":"2012","journal-title":"Lancet Infect Dis"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Granoff DM (2012) European Medicines Agency Recommends Approval of a Broadly Protective Vaccine against Serogroup B Meningococcal Disease. Pediatr Infect Dis J <comment>DOI: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/dx.doi.org\/10.1097\/INF.0b013e318282942f\" xlink:type=\"simple\">10.1097\/INF.0b013e318282942f<\/ext-link><\/comment>","DOI":"10.1097\/INF.0b013e318282942f"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"91ra62","DOI":"10.1126\/scitranslmed.3002234","article-title":"Rational design of a meningococcal antigen inducing broad protective immunity","volume":"3","author":"M Scarselli","year":"2011","journal-title":"Sci Transl Med"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.1128\/IAI.00033-08","article-title":"Bactericidal antibody responses induced by meningococcal recombinant chimeric factor H-binding protein vaccines","volume":"76","author":"PT Beernink","year":"2008","journal-title":"Infect Immun"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"10834","DOI":"10.1073\/pnas.0603940103","article-title":"A universal vaccine for serogroup B meningococcus","volume":"103","author":"MM Giuliani","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1086\/589308","article-title":"Bactericidal antibody responses elicited by a meningococcal outer membrane vesicle vaccine with overexpressed factor H-binding protein and genetically attenuated endotoxin","volume":"198","author":"O Koeberling","year":"2008","journal-title":"J Infect Dis"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"4728","DOI":"10.1016\/j.vaccine.2011.04.095","article-title":"Immunogenicity of a meningococcal native outer membrane vesicle vaccine with attenuated endotoxin and over-expressed factor H binding protein in infant rhesus monkeys","volume":"29","author":"O Koeberling","year":"2011","journal-title":"Vaccine"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1016\/j.vaccine.2009.12.027","article-title":"Frequency of factor H-binding protein modular groups and susceptibility to cross-reactive bactericidal activity in invasive meningococcal isolates","volume":"28","author":"R Pajon","year":"2010","journal-title":"Vaccine"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1128\/IAI.00891-10","article-title":"Characterization of diverse subvariants of the meningococcal factor H (fH) binding protein for their ability to bind fH, to mediate serum resistance, and to induce bactericidal antibodies","volume":"79","author":"KL Seib","year":"2011","journal-title":"Infect Immun"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/j.vaccine.2010.11.064","article-title":"Influence of sequence variability on bactericidal activity sera induced by Factor H binding protein variant 1.1","volume":"29","author":"B Brunelli","year":"2011","journal-title":"Vaccine"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"6086","DOI":"10.1016\/j.vaccine.2010.06.083","article-title":"Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease","volume":"28","author":"HQ Jiang","year":"2010","journal-title":"Vaccine"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"e1302","DOI":"10.1371\/journal.pntd.0001302","article-title":"Meningococcal factor h binding proteins in epidemic strains from Africa: implications for vaccine development","volume":"5","author":"R Pajon","year":"2011","journal-title":"PLoS Negl Trop Dis"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"e1002688","DOI":"10.1371\/journal.ppat.1002688","article-title":"The effect of human factor H on immunogenicity of meningococcal native outer membrane vesicle vaccines with over-expressed factor H binding protein","volume":"8","author":"PT Beernink","year":"2012","journal-title":"PLoS Pathog"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"3606","DOI":"10.4049\/jimmunol.1003470","article-title":"A meningococcal factor H binding protein mutant that eliminates factor H binding enhances protective antibody responses to vaccination","volume":"186","author":"PT Beernink","year":"2011","journal-title":"J Immunol"},{"key":"ref45","first-page":"2667","article-title":"Design of meningococcal factor H binding protein mutant vaccines that do not bind human complement factor H. Infect Immun","volume":"80","author":"R Pajon","year":"2012"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"e46019","DOI":"10.1371\/journal.pone.0046019","article-title":"Molecular Characterization of Invasive Meningococcal Isolates from Countries in the African Meningitis Belt before Introduction of a Serogroup A Conjugate Vaccine","volume":"7","author":"DA Caugant","year":"2012","journal-title":"PLoS One"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1016\/j.molimm.2009.02.021","article-title":"A region of the N-terminal domain of meningococcal factor H-binding protein that elicits bactericidal antibody across antigenic variant groups","volume":"46","author":"PT Beernink","year":"2009","journal-title":"Mol Immunol"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"3751","DOI":"10.1128\/IAI.05182-11","article-title":"Complement-mediated bactericidal activity of anti-factor H binding protein monoclonal antibodies against the meningococcus relies upon blocking factor H binding","volume":"79","author":"S Giuntini","year":"2011","journal-title":"Infect Immun"},{"key":"ref49","first-page":"113","article-title":"Teasing apart structural determinants of \u2018toxicity\u2019 and \u2018adjuvanticity\u2019: implications for meningococcal vaccine development","volume":"10","author":"L Steeghs","year":"2004","journal-title":"J Endotoxin Res"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1128\/CVI.00403-08","article-title":"Meningococcal outer membrane vesicle vaccines derived from mutant strains engineered to express factor H binding proteins from antigenic variant groups 1 and 2","volume":"16","author":"O Koeberling","year":"2009","journal-title":"Clin Vaccine Immunol"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"5057","DOI":"10.1016\/j.vaccine.2010.05.006","article-title":"Design and evaluation in mice of a broadly protective meningococcal group B native outer membrane vesicle vaccine","volume":"28","author":"WD Zollinger","year":"2010","journal-title":"Vaccine"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1128\/CVI.05020-11","article-title":"Meningococcal group C and W135 immunological hyporesponsiveness in african toddlers","volume":"18","author":"H Findlow","year":"2011","journal-title":"Clin Vaccine Immunol"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1001\/archpedi.159.10.907","article-title":"Safety, immunogenicity, and immune memory of a novel meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine (MCV-4) in healthy adolescents","volume":"159","author":"H Keyserling","year":"2005","journal-title":"Arch Pediatr Adolesc Med"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"5606","DOI":"10.4049\/jimmunol.172.9.5606","article-title":"Protective activity of monoclonal antibodies to genome-derived neisserial antigen 1870, a <italic>Neisseria meningitidis<\/italic> candidate vaccine","volume":"172","author":"JA Welsch","year":"2004","journal-title":"J Immunol"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1128\/CDLI.5.4.479-485.1998","article-title":"A modified enzyme-linked immunosorbent assay for measurement of antibody responses to meningococcal C polysaccharide that correlate with bactericidal responses","volume":"5","author":"DM Granoff","year":"1998","journal-title":"Clin Diagn Lab Immunol"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0008-6215(96)00305-9","article-title":"Structural basis of the <italic>Neisseria meningitidis<\/italic> immunotypes including the L4 and L7 immunotypes","volume":"298","author":"G Kogan","year":"1997","journal-title":"Carbohydr Res"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/j.1574-6968.2001.tb10675.x","article-title":"Detection of the lst gene in different serogroups and LOS immunotypes of <italic>Neisseria meningitidis<\/italic>","volume":"199","author":"RS Tsang","year":"2001","journal-title":"FEMS Microbiol Lett"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1006\/mpat.1995.0071","article-title":"Sialylation of neisserial lipopolysaccharide: a major influence on pathogenicity","volume":"19","author":"H Smith","year":"1995","journal-title":"Microb Pathog"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1086\/597806","article-title":"Meningococcal factor H-binding protein variants expressed by epidemic capsular group A, W-135, and X strains from Africa","volume":"199","author":"PT Beernink","year":"2009","journal-title":"J Infect Dis"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"5267","DOI":"10.1128\/IAI.60.12.5267-5282.1992","article-title":"Clonal and antigenic analysis of serogroup A <italic>Neisseria meningitidis<\/italic> with particular reference to epidemiological features of epidemic meningitis in the People\u2019s Republic of China","volume":"60","author":"JF Wang","year":"1992","journal-title":"Infect Immun"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"6390","DOI":"10.1128\/jb.177.22.6390-6400.1995","article-title":"The physical map of the chromosome of a serogroup A strain of <italic>Neisseria meningitidis<\/italic> shows complex rearrangements relative to the chromosomes of the two mapped strains of the closely related species <italic>N. gonorrhoeae<\/italic>","volume":"177","author":"JA Dempsey","year":"1995","journal-title":"J Bacteriol"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1128\/CVI.00542-10","article-title":"A critical threshold of meningococcal factor h binding protein expression is required for increased breadth of protective antibodies elicited by native outer membrane vesicle vaccines","volume":"18","author":"O Koeberling","year":"2011","journal-title":"Clin Vaccine Immunol"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"e1001027","DOI":"10.1371\/journal.ppat.1001027","article-title":"The meningococcal vaccine candidate neisserial surface protein A (NspA) binds to factor H and enhances meningococcal resistance to complement","volume":"6","author":"LA Lewis","year":"2010","journal-title":"PLoS Pathog"},{"key":"ref64","doi-asserted-by":"crossref","first-page":"5812","DOI":"10.1016\/j.vaccine.2012.07.032","article-title":"Characterization of size, structure and purity of serogroup X <italic>Neisseria meningitidis<\/italic> polysaccharide, and development of an assay for quantification of human antibodies","volume":"30","author":"O Xie","year":"2012","journal-title":"Vaccine"},{"key":"ref65","doi-asserted-by":"crossref","first-page":"A97","DOI":"10.1016\/j.vaccine.2007.04.049","article-title":"The Meningitis Vaccine Project","volume":"25","author":"FM LaForce","year":"2007","journal-title":"Vaccine"},{"key":"ref66","doi-asserted-by":"crossref","first-page":"5574","DOI":"10.1016\/j.vaccine.2009.07.036","article-title":"Chemistry of a new investigational quadrivalent meningococcal conjugate vaccine that is immunogenic at all ages","volume":"27","author":"M Broker","year":"2009","journal-title":"Vaccine"},{"key":"ref67","doi-asserted-by":"crossref","unstructured":"Jackson LA, Jacobson RM, Reisinger KS, Anemona A, Danzig LE, et al.. (2009) A randomized trial to determine the tolerability and immunogenicity of a quadrivalent meningococcal glycoconjugate vaccine in healthy adolescents. Pediatr Infect Dis J: 86\u201391.","DOI":"10.1097\/INF.0b013e31818a0237"},{"key":"ref68","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1097\/INF.0b013e31818e037d","article-title":"Immunogenicity and immune memory of a nonadjuvanted quadrivalent meningococcal glycoconjugate vaccine in infants","volume":"28","author":"KP Perrett","year":"2009","journal-title":"Pediatr Infect Dis J"},{"key":"ref69","doi-asserted-by":"crossref","first-page":"5513","DOI":"10.1016\/j.vaccine.2010.06.026","article-title":"Glycoconjugate vaccines and immune interference: A review","volume":"28","author":"R Dagan","year":"2010","journal-title":"Vaccine"},{"key":"ref70","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.1016\/j.vaccine.2007.01.022","article-title":"Safety review: two outer membrane vesicle (OMV) vaccines against systemic <italic>Neisseria meningitidis<\/italic> serogroup B disease","volume":"25","author":"H Nokleby","year":"2007","journal-title":"Vaccine"},{"key":"ref71","unstructured":"Sierra GV, Campa HC, Varcacel NM, Garcia IL, Izquierdo PL, et al.. (1991) Vaccine against group B <italic>Neisseria meningitidis<\/italic>: protection trial and mass vaccination results in Cuba. NIPH Ann 14: 195\u2013207; discussion 208\u2013110."},{"key":"ref72","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1093\/ije\/dyn228","article-title":"Use of an observational cohort study to estimate the effectiveness of the New Zealand group B meningococcal vaccine in children aged under 5 years","volume":"38","author":"Y Galloway","year":"2009","journal-title":"Int J Epidemiol"},{"key":"ref73","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1365-3083.2012.02709.x","article-title":"An outer membrane vesicle vaccine for prevention of serogroup A and W-135 meningococcal disease in the African meningitis belt","volume":"76","author":"G Norheim","year":"2012","journal-title":"Scand J Immunol"},{"key":"ref74","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1001\/jama.281.16.1520","article-title":"Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile","volume":"281","author":"JW Tappero","year":"1999","journal-title":"JAMA"},{"key":"ref75","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/j.1365-2958.1994.tb01014.x","article-title":"The porA gene in serogroup A meningococci: evolutionary stability and mechanism of genetic variation","volume":"12","author":"J Suker","year":"1994","journal-title":"Mol Microbiol"},{"key":"ref76","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/j.1365-2958.1992.tb01493.x","article-title":"Role of horizontal genetic exchange in the antigenic variation of the class 1 outer membrane protein of <italic>Neisseria meningitidis<\/italic>","volume":"6","author":"IM Feavers","year":"1992","journal-title":"Mol Microbiol"},{"key":"ref77","doi-asserted-by":"crossref","first-page":"A8","DOI":"10.1016\/j.vaccine.2007.04.033","article-title":"Molecular surveillance of meningococcal meningitis in Africa","volume":"25","author":"DA Caugant","year":"2007","journal-title":"Vaccine"},{"key":"ref78","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1128\/JCM.44.3.861-871.2006","article-title":"Characterization of <italic>Neisseria meningitidis<\/italic> isolates from recent outbreaks in Ethiopia and comparison with those recovered during the epidemic of 1988 to 1989","volume":"44","author":"G Norheim","year":"2006","journal-title":"J Clin Microbiol"},{"key":"ref79","doi-asserted-by":"crossref","first-page":"5129","DOI":"10.1128\/JCM.43.10.5129-5135.2005","article-title":"Molecular epidemiology of <italic>Neisseria meningitidis<\/italic> isolated in the African Meningitis Belt between 1988 and 2003 shows dominance of sequence type 5 (ST-5) and ST-11 complexes","volume":"43","author":"P Nicolas","year":"2005","journal-title":"J Clin Microbiol"},{"key":"ref80","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1128\/CDLI.7.3.390-395.2000","article-title":"Sequence variation in the porA gene of a clone of <italic>Neisseria meningitidis<\/italic> during epidemic spread","volume":"7","author":"J Jelfs","year":"2000","journal-title":"Clin Diagn Lab Immunol"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/j.vaccine.2010.12.039","article-title":"A phase 1 study of a meningococcal native outer membrane vesicle vaccine made from a group B strain with deleted <italic>lpxL1<\/italic> and <italic>synX<\/italic>, over-expressed factor H binding protein, two PorAs and stabilized OpcA expression","volume":"29","author":"PB Keiser","year":"2011","journal-title":"Vaccine"},{"key":"ref82","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1002\/pmic.200500164","article-title":"Outer membrane vesicles from group B <italic>Neisseria meningitidis<\/italic> delta <italic>gna33<\/italic> mutant: proteomic and immunological comparison with detergent-derived outer membrane vesicles","volume":"6","author":"G Ferrari","year":"2006","journal-title":"Proteomics"},{"key":"ref83","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1128\/CVI.00125-08","article-title":"<italic>Neisseria meningitidis<\/italic> PorB, a Toll-like receptor 2 ligand, improves the capacity of <italic>Francisella tularensis<\/italic> lipopolysaccharide to protect mice against experimental tularemia","volume":"15","author":"D Chiavolini","year":"2008","journal-title":"Clin Vaccine Immunol"},{"key":"ref84","doi-asserted-by":"crossref","first-page":"749","DOI":"10.2217\/fmb.10.41","article-title":"Innate immune function of the neisserial porins and the relationship to vaccine adjuvant activity","volume":"5","author":"LM Wetzler","year":"2010","journal-title":"Future Microbiol"},{"key":"ref85","first-page":"4401","article-title":"TLR4-dependent adjuvant activity of <italic>Neisseria meningitidis<\/italic> lipid A. Vaccine","volume":"25","author":"S Zughaier","year":"2007"},{"key":"ref86","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1016\/j.vaccine.2010.12.075","article-title":"Cooperative serum bactericidal activity between human antibodies to meningococcal factor H binding protein and Neisserial heparin binding antigen","volume":"29","author":"DM Vu","year":"2011","journal-title":"Vaccine"},{"key":"ref87","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1017\/S0950268807008825","article-title":"The changing face of meningococcal disease in West Africa","volume":"135","author":"B Greenwood","year":"2007","journal-title":"Epidemiol Infect"},{"key":"ref88","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1016\/S0140-6736(07)61016-2","article-title":"Epidemic meningitis, meningococcaemia, and <italic>Neisseria meningitidis<\/italic>","volume":"369","author":"DS Stephens","year":"2007","journal-title":"Lancet"},{"key":"ref89","doi-asserted-by":"crossref","first-page":"e19717","DOI":"10.1371\/journal.pone.0019717","article-title":"Epidemiology, molecular characterization and antibiotic resistance of <italic>Neisseria meningitidis<\/italic> from patients &lt;\/ = 15 years in Manhica, rural Mozambique","volume":"6","author":"AB Ibarz-Pavon","year":"2011","journal-title":"PLoS One"},{"key":"ref90","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1080\/00365540310016042","article-title":"Neisserial Opa proteins: impact on colonization, dissemination and immunity","volume":"35","author":"SD Gray-Owen","year":"2003","journal-title":"Scand J Infect Dis"},{"key":"ref91","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1046\/j.1462-5822.1999.00017.x","article-title":"Molecular analysis of neisserial Opa protein interactions with the CEA family of receptors: identification of determinants contributing to the differential specificities of binding","volume":"1","author":"A Popp","year":"1999","journal-title":"Cell Microbiol"},{"key":"ref92","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1128\/CDLI.2.1.69-72.1995","article-title":"Serotypes and subtypes of <italic>Neisseria meningitidis<\/italic>: results of an international study comparing sensitivities and specificities of monoclonal antibodies","volume":"2","author":"JT Poolman","year":"1995","journal-title":"Clin Diagn Lab Immunol"},{"key":"ref93","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1073\/pnas.95.6.3140","article-title":"Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms","volume":"95","author":"MC Maiden","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref94","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1186\/1471-2105-11-595","article-title":"BIGSdb: Scalable analysis of bacterial genome variation at the population level","volume":"11","author":"KA Jolley","year":"2010","journal-title":"BMC Bioinformatics"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0066536","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,26]],"date-time":"2022-02-26T01:54:53Z","timestamp":1645840493000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0066536"}},"subtitle":[],"editor":[{"given":"Caroline L.","family":"Trotter","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2013,6,21]]},"references-count":94,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2013,6,21]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0066536","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2013,6,21]]}}}